- Illumina (NASDAQ:ILMN -2%) has acquired privately held Edico Genome for an undisclosed sum. The San Diego, CA-based firm provides data analysis acceleration solutions for next-generation sequencing (NGS) via its DRAGEN Bio-IT platform.
- SVP of Product Development Susan Tousi says, “Our acquisition of Edico Genome is a big step toward realizing the vision of reducing sequencing data acquisition and analysis to a push-button, standardized process. We expect to build on the solid foundation of DRAGEN to deliver a more streamlined and integrated sample to answer experience for our customers.”